专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08399457B2 Pharmaceutical compounds 失效
标题翻译：药物化合物
公开(公告)号：US08399457B2
公开(公告)日：2013-03-19
申请号：US12512818
申请日：2009-07-30
申请人： Paolo Lazzari , Giovanni Loriga , Stefania Ruiu , Ilaria Manca , Luca Pani , Gerard Aime Pinna
发明人： Paolo Lazzari , Giovanni Loriga , Stefania Ruiu , Ilaria Manca , Luca Pani , Gerard Aime Pinna
IPC分类号： A61P21/02 , A61K31/551 , C07D487/08
CPC分类号： C07D487/08
摘要： Nonane and decane diazabicyclic derivatives having homopiperazine as main ring, having affinity for the opioidergic μ and/or δ and/or k receptors and/or for all their receptorial subclasses, with central and/or peripheral activity, having formula (I), the isomeric forms and their mixtures included, wherein one or more atoms are in the corresponding isotopic forms: wherein: n is an integer equal to 1 or 2; one of the substituents R and R1 of the nitrogen atoms of the diazabicyclic ring is a —C(O)—RB group, wherein RB is a C1-C10 alkyl group, linear or branched when possible, the other remained substituent of R and R1 has the meanings reported in the description.
摘要翻译：具有高哌嗪作为主环的壬烷和癸烷二氮杂双环衍生物，对具有式（I）的具有中枢和/或外周活性的对阿片样物质的μ和/或δ和/或k受体和/或所有其接受的亚类具有亲和力，异构体及其混合物，其中一个或多个原子为相应的同位素形式：其中：n为等于1或2的整数; 二氮杂双环的氮原子的取代基R和R中的一个是-C（O）-RB基团，其中R b是C 1 -C 10烷基，如果可能的话是直链或支链的，另一个保留R和R 1的取代基具有说明书中报道的含义。

2. 发明申请

US20100216785A1 PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：药物组合物
公开(公告)号：US20100216785A1
公开(公告)日：2010-08-26
申请号：US12712950
申请日：2010-02-25
申请人： Paolo LAZZARI , Giovanni LORIGA , Ilaria MANCA , Gerard Aime PINNA , Luca PANI
发明人： Paolo LAZZARI , Giovanni LORIGA , Ilaria MANCA , Gerard Aime PINNA , Luca PANI
IPC分类号： A61K31/416 , C07D231/54 , C07D491/044 , C07D405/12 , C07D491/048 , A61K31/454 , A61K31/5377 , A61P37/00 , A61P9/10 , A61P19/10 , A61P11/00 , A61P29/00 , A61P27/02 , A61P25/28 , A61P25/00 , A61P3/00 , A61P13/00 , A61P17/00 , A61P15/00
CPC分类号： C07D231/54 , A61K9/0048 , A61K9/1075 , A61K31/4155 , A61K31/416 , C07D405/12 , C07D491/04
摘要： Microemulsions of pharmaceutical compositions comprising, the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers, forming organized structures as: aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, O) from 0.01 to 95% of one or more oils selected from esters of C4-C32 acids or C4-C32 acids, PA) from 0.001 to 90% of compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors of formula A′: AD) from 0 to 60% by weight of one or more compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, water or a saline aqueous solution the difference to 100%, wherein the ratio by weight S)/PA) is lower than that of microemulsions wherein component O) is absent.
摘要翻译：药物组合物的微乳液包含以下组分（重量％），组分的总和为100％：S）0.01至95％的一种或多种选自表面活性剂，聚合物的化合物，形成有组织的结构，如：聚集体，胶束，其中它们被溶解的液体中的液晶，囊泡，O）0.01至95％的一种或多种选自C 4 -C 32酸或C 4 -C 32酸的酯的油，PA），0.001至90％的化合物对一种或多种选自水和/或油极性改性剂的化合物的0至60重量％具有对式A'：AD的CB1和/或CB2大麻素受体受体的亲和性，组分S的膜曲率的改性剂），辅助表面活性剂，水或盐水溶液的差异为100％，其中重量比S / PA）低于其中组分O）不存在的微乳液。

3. 发明申请

US20100215741A1 PHARMACEUTICAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：US20100215741A1
公开(公告)日：2010-08-26
申请号：US12712879
申请日：2010-02-25
申请人： Paolo LAZZARI , Giovanni Loriga , Ilaria Manca , Gerard Aime Pinna , Luca Pani
发明人： Paolo LAZZARI , Giovanni Loriga , Ilaria Manca , Gerard Aime Pinna , Luca Pani
IPC分类号： A61K9/36 , C07D231/54 , A61K31/416 , C07D491/044 , C07D405/12 , A61K31/5377 , A61P37/00 , A61P9/10 , A61P19/10 , A61P11/00 , A61P29/00 , A61P27/02 , A61P25/28 , A61P25/00 , A61P3/00 , A61P13/00 , A61P17/00 , A61K31/4162 , C07D491/048
CPC分类号： C07D231/54 , C07D491/04
摘要： Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.
摘要翻译：具有包含一个苯基和一个吡唑环的稠合结构的缩合三环化合物通过包含5至8个具有对中枢神经系统和/或外周活性的对CB1和/或CB2受体的亲和力的中心环相互连接，的式（I）：其中各种取代基如说明书中所定义。化合物对CB1和/或CB2大麻素能受体具有亲和力。

4. 发明申请

US20100215745A1 COMPOSITIONS OF SPORES OF NON PATHOGENIC BACTERIA 失效
标题翻译：非致病性细菌的组成
公开(公告)号：US20100215745A1
公开(公告)日：2010-08-26
申请号：US12712647
申请日：2010-02-25
申请人： Paolo LAZZARI , Paolo Fadda , Luca Pani
发明人： Paolo LAZZARI , Paolo Fadda , Luca Pani
IPC分类号： A61K35/74 , A61P1/00
CPC分类号： A61K35/742 , A23K10/18 , A23L29/10 , A23L33/135 , A61K9/1075 , A61K9/1274
摘要： Liquid-based phamaceutical and/or veterinary and/or nutraceutical compositions comprising non pathogenic sporogenic bacteria, component SP), and the following components: O) from 0.001 to 95% by weight of one or more oils selected from esters of C4-C32 acids, C4-C32, S) from 0 to 90% by weight of one or more amphiphilic compounds, selected from surfactants, polymers forming organized structures such as aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, AD) from 0 to 60% by weight of one or more additive compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, PA) from 0.001 to 70% of one or more compounds selected from food supplements and pharmaceutical and/or veterinary active principles, W) from 0.1 to 99.9% by weight of water or saline aqueous solution, optionally buffered, the sum of the percentages by weight of the components, excluding SP), is 100%,
摘要翻译：液体制药和/或兽医和/或营养保健组合物，包含非致病性致孢杆菌，组分SP）和以下组分：O）0.001至95重量％的一种或多种选自C 4 -C 32酸的酯的油，C 4 -C 32，S）0至90重量％的一种或多种两亲化合物，其选自表面活性剂，形成有组织结构的聚合物，例如聚集体，胶束，液晶，囊泡，在它们被溶解的液体中，AD ）0至60重量％的一种或多种选自水和/或油极性改性剂的添加剂化合物，组分S的膜曲率的改性剂），助表面活性剂，PA），0.001至70％的一种或多种更多选自食品添加剂和药物和/或兽用活性成分的化合物，W）0.1至99.9重量％的水或盐水溶液（任选缓冲的）除组分重量除外的百分比之和除外）是 100％，

5. 发明申请

US20100028257A1 PHARMACEUTICAL COMPOUNDS 失效
标题翻译：药物化合物
公开(公告)号：US20100028257A1
公开(公告)日：2010-02-04
申请号：US12512818
申请日：2009-07-30
申请人： Paolo LAZZARI , Giovanni LORIGA , Stefania RUIU , Ilaria MANCA , Luca PANI , Gerard Aime PINNA
发明人： Paolo LAZZARI , Giovanni LORIGA , Stefania RUIU , Ilaria MANCA , Luca PANI , Gerard Aime PINNA
IPC分类号： A61K51/04 , C07D241/38 , A61K31/4995 , A61K39/44 , A61P29/00 , A61P25/32 , A61P25/36 , A61P3/04 , A61P25/24 , A61P35/00 , A61P27/06 , A61P27/02 , A61P25/34 , A61P1/00 , A61P17/00
CPC分类号： C07D487/08
摘要： Nonane and decane diazabicyclic derivatives having homopiperazine as main ring, having affinity for the opioidergic μ and/or δ and/or k receptors and/or for all their receptorial subclasses, with central and/or peripheral activity, having formula (I), the isomeric forms and their mixtures included, wherein one or more atoms are in the corresponding isotopic forms: wherein: n is an integer equal to 1 or 2; one of the substituents R and R1 of the nitrogen atoms of the diazabicyclic ring is a —C(O)—RB group; wherein RB is a C1-C10 alkyl group, linear or branched when possible, the other remained substituent of R and R1 has the meanings reported in the description.
摘要翻译：具有高哌嗪作为主环的壬烷和癸烷二氮杂双环衍生物，对具有式（I）的中枢和/或外周活性对阿片样物质μ和/或δ和/或k受体和/或所有其接受亚类具有亲和性，具有式异构体及其混合物，其中一个或多个原子为相应的同位素形式：其中：n为等于1或2的整数; 二氮杂双环的氮原子的取代基R和R1之一是-C（O）-RB基团; 其中RB是C1-C10烷基，如果可能的话是直链或支链的，另一个是R和R 1的取代基具有说明书中报道的含义。

6. 发明申请

US20130017149A1 PHARMACEUTICAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：US20130017149A1
公开(公告)日：2013-01-17
申请号：US13619712
申请日：2012-09-14
申请人： Paolo LAZZARI , Giovanni Loriga , Ilaria Manca , Gerard Aime Pinna , Luca Pani
发明人： Paolo LAZZARI , Giovanni Loriga , Ilaria Manca , Gerard Aime Pinna , Luca Pani
IPC分类号： C07D231/54 , C07D491/044 , A61K31/4162 , C07D491/048 , C07D405/12 , C07D401/12 , A61K31/454 , A61K31/5377 , C07D491/052 , A61K9/36 , A61K9/14 , A61K51/04 , A61P37/00 , A61P13/12 , A61P9/10 , A61P29/00 , A61P25/00 , A61P27/02 , A61P11/00 , A61P11/06 , A61P19/02 , A61P37/08 , A61P11/02 , A61P17/00 , A61P27/14 , A61P25/22 , A61P25/18 , A61P25/24 , A61P25/30 , A61P25/32 , A61P1/08 , A61P25/08 , A61P25/16 , A61P25/28 , A61P3/04 , A61P3/00 , A61P1/00 , A61P13/10 , A61P9/00 , A61P13/00 , A61P15/00 , A61P15/08 , A61P19/10 , A61P3/06 , A61P3/10 , A61K31/416 , B82Y5/00
CPC分类号： C07D231/54 , C07D491/04
摘要： Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.
摘要翻译：具有包含一个苯基和一个吡唑环的稠合结构的缩合三环化合物通过包含5至8个具有对中枢神经系统和/或外周活性的对CB1和/或CB2受体的亲和力的中心环相互连接，的式（I）：其中各种取代基如说明书中所定义。化合物对CB1和/或CB2大麻素能受体具有亲和力。

7. 发明授权

US08329187B2 Compositions of spores of non pathogenic bacteria 失效
标题翻译：非病原菌孢子的组成
公开(公告)号：US08329187B2
公开(公告)日：2012-12-11
申请号：US12712647
申请日：2010-02-25
申请人： Paolo Lazzari , Paolo Fadda , Luca Pani
发明人： Paolo Lazzari , Paolo Fadda , Luca Pani
IPC分类号： A61K39/00 , A61K39/02 , A61K39/07 , A61K39/08
CPC分类号： A61K35/742 , A23K10/18 , A23L29/10 , A23L33/135 , A61K9/1075 , A61K9/1274
摘要： Liquid-based phamaceutical and/or veterinary and/or nutraceutical compositions comprising non pathogenic sporogenic bacteria, component SP), and the following components: O) from 0.001 to 95% by weight of one or more oils selected from esters of C4-C32 acids, C4-C32, S) from 0 to 90% by weight of one or more amphiphilic compounds, selected from surfactants, polymers forming organized structures such as aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, AD) from 0 to 60% by weight of one or more additive compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, PA) from 0.001 to 70% of one or more compounds selected from food supplements and pharmaceutical and/or veterinary active principles, W) from 0.1 to 99.9% by weight of water or saline aqueous solution, optionally buffered, the sum of the percentages by weight of the components, excluding SP), is 100%.
摘要翻译：液体制药和/或兽医和/或营养保健组合物，包含非致病性致孢杆菌，组分SP）和以下组分：O）0.001至95重量％的一种或多种选自C 4 -C 32酸的酯的油，C 4 -C 32，S）0至90重量％的一种或多种两亲化合物，其选自表面活性剂，形成有组织结构的聚合物，例如聚集体，胶束，液晶，囊泡，在它们被溶解的液体中，AD ）0至60重量％的一种或多种选自水和/或油极性改性剂的添加剂化合物，组分S的膜曲率的改性剂），助表面活性剂，PA），0.001至70％的一种或多种更多选自食品添加剂和药物和/或兽用活性成分的化合物，W）0.1至99.9重量％的水或盐水溶液（任选缓冲的）除组分重量除外的百分比之和除外）是 100％。

8. 发明授权

US08227620B2 Pharmaceutical compounds 失效
标题翻译：药物化合物
公开(公告)号：US08227620B2
公开(公告)日：2012-07-24
申请号：US12645415
申请日：2009-12-22
申请人： Paolo Lazzari , Stefania Ruiu , Gerard Aime Pinna , Gabriele Murineddu
发明人： Paolo Lazzari , Stefania Ruiu , Gerard Aime Pinna , Gabriele Murineddu
IPC分类号： A61K31/4155 , A61K31/454
CPC分类号： C07D409/04
摘要： Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors: wherein: R is a group selected from C1-C10 alkyl; aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; A is a group selected from the following: an ether group of formula —(CH2)—O—(CH2)v—R″ wherein v is equal to 1 or 2; R″ is as defined in the present application; a ketone group of formula —C(O)—Z′, wherein Z′ is as defined in the present application; a substituent having an hydroxyl function of formula —CH(OH)—Z′, being as defined in the present application; an amide substituent of formula —C(O)—NH-T′, T′ being as defined in the present application; B is a group as defined in the present application; D is an heteroaryl optionally substituted.
摘要翻译：具有对大麻素能CB1和/或CB2受体的亲和力的下式（I）的吡唑衍生物：其中：R是选自C1-C10烷基的基团; 未被取代或具有1-4个取代基的芳基，芳基烷基或芳基烯基，彼此相等或不同; A是选自以下的基团：式 - （CH 2）-O-（CH 2）v -R“的醚基，其中v等于1或2; R“如本申请中所定义; 式-C（O）-Z'的酮基，其中Z'如本申请中所定义; 具有式-CH（OH）-Z'羟基官能团的取代基，如本申请中所定义; 式-C（O）-NH-T'，T'的酰胺取代基如本申请中所定义; B是本申请中定义的组; D是任选取代的杂芳基。

9. 发明申请

US20110152238A1 PHARMACEUTICAL COMPOUNDS 失效
标题翻译：药物化合物
公开(公告)号：US20110152238A1
公开(公告)日：2011-06-23
申请号：US12966371
申请日：2010-12-13
申请人： Paolo LAZZARI , Giovanni Loriga , Stefania Ruiu , Gabrieie Murineddu , Luca Pani , Gerard Aime Pinna
发明人： Paolo LAZZARI , Giovanni Loriga , Stefania Ruiu , Gabrieie Murineddu , Luca Pani , Gerard Aime Pinna
IPC分类号： A61K31/4995 , C07D487/18 , C07D471/08 , C07D487/08 , A61K31/55 , A61K31/439 , A61K31/551 , A61K31/4748 , A61P29/00 , A61P25/04 , A61P25/30 , A61P25/32 , A61P1/10 , A61P1/12 , A61P1/00 , A61P1/08 , A61P17/00 , A61P3/04 , A61P25/22 , A61P25/24 , A61P25/34 , A61P15/00 , A61P27/02 , A61P27/06 , A61P35/00 , A61P19/02 , A61P17/06 , A61P11/06 , A61P9/00 , A61P13/00 , A61P25/16 , A61P25/28 , A61P3/10 , A61P9/10 , A61P5/00 , A61P37/00 , A61P37/06
CPC分类号： C07D471/08 , C07D487/08
摘要： Diazapolycyclic compounds having affinity for the opioidergic receptors, preferably for the delta opioidergic receptors, with central and/or peripheral activity, having formula: A1-D1-T1 (I) wherein: A1 is a group of formula (II): wherein: R1 is phenyl wherein one of the ring hydrogen atoms is substituted with a group selected from C(O)R′, C(O)OR′, C(O)NHR′ or C(O)NR3R4, R′, R3 and R4, being as defined in the application; R2 is phenyl, optionally substituted D1 is a diazapolycyclic group T1 is a group selected from H, alkyl, alkenyl, alkynyl and from the following optionally substituted groups: cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl or heteroarylalkyl, and their hydrates and solvates and pharmaceutically acceptable salts.
摘要翻译： A1-D1-T1（Ⅰ）其中：A1是式（Ⅱ）的基团：其中：R1（ⅰ），其中R1为具有中性和/或外周活性的阿片样物质受体的阿片样物质受体，是其中一个环状氢原子被选自C（O）R'，C（O）OR'，C（O）NHR'或C（O）NR 3 R 4，R'，R 3和R 4的基团取代的苯基，正如申请中所定义的; R2是苯基，任意取代的D1是一个二氮杂多环基团，T1是选自H，烷基，烯基，炔基和下列任选取代的基团：环烷基，杂环烷基，芳基，杂芳基，环烷基烷基，杂环烷基烷基，芳基烷基或杂芳基烷基，水合物和溶剂化物和药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式